PT1143955E - Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete - Google Patents
Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabeteInfo
- Publication number
- PT1143955E PT1143955E PT99964313T PT99964313T PT1143955E PT 1143955 E PT1143955 E PT 1143955E PT 99964313 T PT99964313 T PT 99964313T PT 99964313 T PT99964313 T PT 99964313T PT 1143955 E PT1143955 E PT 1143955E
- Authority
- PT
- Portugal
- Prior art keywords
- diabetes
- treatment
- combination
- insulin
- insulin sensitizers
- Prior art date
Links
- 229940122355 Insulin sensitizer Drugs 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 abstract 1
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 abstract 1
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 abstract 1
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 abstract 1
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11471898P | 1998-12-24 | 1998-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1143955E true PT1143955E (pt) | 2005-11-30 |
Family
ID=22357016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99964313T PT1143955E (pt) | 1998-12-24 | 1999-12-22 | Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1143955B1 (https=) |
| JP (1) | JP2003515523A (https=) |
| KR (3) | KR20060114724A (https=) |
| CN (3) | CN101164618A (https=) |
| AT (1) | ATE300288T1 (https=) |
| AU (1) | AU771039B2 (https=) |
| BR (1) | BR9917005A (https=) |
| CA (1) | CA2354053A1 (https=) |
| CZ (1) | CZ20012353A3 (https=) |
| DE (1) | DE69926400T2 (https=) |
| DK (1) | DK1143955T3 (https=) |
| ES (1) | ES2246586T3 (https=) |
| HK (1) | HK1046863B (https=) |
| HU (1) | HUP0402506A3 (https=) |
| ID (1) | ID30237A (https=) |
| IL (2) | IL143569A0 (https=) |
| MX (1) | MXPA01006511A (https=) |
| NO (1) | NO20013115L (https=) |
| NZ (1) | NZ512219A (https=) |
| PL (1) | PL352756A1 (https=) |
| PT (1) | PT1143955E (https=) |
| RU (2) | RU2227749C2 (https=) |
| SK (1) | SK9172001A3 (https=) |
| WO (1) | WO2000038666A2 (https=) |
| ZA (1) | ZA200105016B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| ATE246197T1 (de) | 1998-09-09 | 2003-08-15 | Metabasis Therapeutics Inc | Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren |
| CA2396713A1 (en) | 1999-12-22 | 2001-07-05 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| US6919322B2 (en) | 2000-03-08 | 2005-07-19 | Metabasis Therapeutics, Inc. | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors |
| US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| IL153513A0 (en) * | 2000-07-06 | 2003-07-06 | Metabasis Therapeutics Inc | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES |
| CA2429426A1 (en) | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
| NZ536328A (en) | 2002-05-13 | 2007-11-30 | Metabasis Therapeutics Inc | Novel phosphonic acid based prodrugs of PMEA and its analogues |
| AU2003235501A1 (en) | 2002-05-13 | 2003-11-11 | Metabasis Therapeutics, Inc. | PMEA and PMPA cyclic producing synthesis |
| AU2003264256A1 (en) * | 2002-09-04 | 2004-03-29 | Dsm Ip Assets B.V. | A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| EA009919B1 (ru) * | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| CA2551611C (en) * | 2003-12-26 | 2013-06-25 | Kyowa Kirin Co., Ltd. | Thiazole derivatives for treating or preventing parkinson's disease |
| JP2008510018A (ja) * | 2004-08-18 | 2008-04-03 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質 |
| WO2006064744A1 (ja) * | 2004-12-13 | 2006-06-22 | Daiichi Sankyo Company, Limited | 糖尿病の治療のための医薬組成物 |
| BRPI0519015A2 (pt) * | 2004-12-15 | 2008-12-23 | Daiichi Sankyo Co Ltd | composiÇço farmacÊutica, agente profilÁtico ou agente terapÊutico, agentes para melhorar a funÇço das cÉlulas b no pÂncreas, e para a reduÇço da razço da hemoglobina glicosilada, e, usos da 5-[4-(6-metàxi-1-metil-1h-benzimidazol-2-ilmetàxi)benzi l] tiazolidina-2,4-diona ou de um sal farmacologicamente aceitÁvel da mesma e de um inibidor de fbpase, e do 2-amino-5-isobutil-4-[2-[5-(n,n'-bis((s)-1etoxicarbonil)eti l) fosfonamido] furanil} tiazol ou de um sal farmacologicamente aceitÁvel do mesmo |
| EP1889618A4 (en) * | 2005-05-27 | 2010-11-24 | Daiichi Sankyo Co Ltd | Combined drug for treating diabetes |
| WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
| WO2008063842A2 (en) | 2006-11-02 | 2008-05-29 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| US9631825B2 (en) | 2012-12-18 | 2017-04-25 | Nortek Air Solutions, Llc | Air filter assembly |
| JP2017512183A (ja) | 2014-02-13 | 2017-05-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| CN105481896A (zh) * | 2015-12-03 | 2016-04-13 | 浙江大学 | 一种地马格列的制备方法 |
| CN113416739B (zh) * | 2021-06-24 | 2022-04-19 | 黑龙江八一农垦大学 | 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968790A (en) * | 1988-08-12 | 1990-11-06 | American Cyanamid Company | Antidiabetic phosphates |
| JPH03157377A (ja) * | 1988-11-18 | 1991-07-05 | Takeda Chem Ind Ltd | チオ尿素誘導体及びａｇｅ生成阻害剤 |
| EP0427799B1 (en) * | 1989-01-24 | 1994-11-30 | Gensia, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| US6054587A (en) * | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU6452098A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) * | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
-
1999
- 1999-12-22 IL IL14356999A patent/IL143569A0/xx active IP Right Grant
- 1999-12-22 CN CNA2007101628889A patent/CN101164618A/zh active Pending
- 1999-12-22 ES ES99964313T patent/ES2246586T3/es not_active Expired - Lifetime
- 1999-12-22 ID IDW00200101612A patent/ID30237A/id unknown
- 1999-12-22 DE DE69926400T patent/DE69926400T2/de not_active Expired - Lifetime
- 1999-12-22 NZ NZ512219A patent/NZ512219A/xx not_active IP Right Cessation
- 1999-12-22 CN CNA2005100806150A patent/CN1714866A/zh active Pending
- 1999-12-22 KR KR1020067022095A patent/KR20060114724A/ko not_active Ceased
- 1999-12-22 KR KR1020017008102A patent/KR100689943B1/ko not_active Expired - Fee Related
- 1999-12-22 CN CNB998163562A patent/CN100352505C/zh not_active Expired - Fee Related
- 1999-12-22 AT AT99964313T patent/ATE300288T1/de active
- 1999-12-22 DK DK99964313T patent/DK1143955T3/da active
- 1999-12-22 BR BR9917005-1A patent/BR9917005A/pt not_active Application Discontinuation
- 1999-12-22 WO PCT/US1999/030713 patent/WO2000038666A2/en not_active Ceased
- 1999-12-22 RU RU2001120726/15A patent/RU2227749C2/ru not_active IP Right Cessation
- 1999-12-22 CA CA002354053A patent/CA2354053A1/en not_active Abandoned
- 1999-12-22 HU HU0402506A patent/HUP0402506A3/hu active IP Right Revival
- 1999-12-22 CZ CZ20012353A patent/CZ20012353A3/cs unknown
- 1999-12-22 MX MXPA01006511A patent/MXPA01006511A/es active IP Right Grant
- 1999-12-22 AU AU20583/00A patent/AU771039B2/en not_active Ceased
- 1999-12-22 JP JP2000590620A patent/JP2003515523A/ja active Pending
- 1999-12-22 SK SK917-2001A patent/SK9172001A3/sk unknown
- 1999-12-22 KR KR1020077008649A patent/KR20070046210A/ko not_active Ceased
- 1999-12-22 PT PT99964313T patent/PT1143955E/pt unknown
- 1999-12-22 EP EP99964313A patent/EP1143955B1/en not_active Expired - Lifetime
- 1999-12-22 PL PL99352756A patent/PL352756A1/xx not_active Application Discontinuation
- 1999-12-22 HK HK02108475.5A patent/HK1046863B/zh not_active IP Right Cessation
-
2001
- 2001-06-05 IL IL143569A patent/IL143569A/en not_active IP Right Cessation
- 2001-06-19 ZA ZA200105016A patent/ZA200105016B/en unknown
- 2001-06-21 NO NO20013115A patent/NO20013115L/no not_active Application Discontinuation
-
2003
- 2003-10-31 RU RU2003132054/14A patent/RU2003132054A/ru not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1143955E (pt) | Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
| EA200100573A1 (ru) | Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии | |
| SG146653A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
| MXPA04002572A (es) | Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol. | |
| DK1284959T3 (da) | Forbindelser til modulering af RAGE-receptoren | |
| WO2002078639A3 (en) | A method of treating proliferative diseases using eg5 inhibitors | |
| ATE191472T1 (de) | Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen | |
| MXPA05000765A (es) | Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos. | |
| BR0315942A (pt) | Tratamento de doenças e condições mediadas pelo aumento de fosforilação | |
| AR045144A1 (es) | Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| TNSN07372A1 (en) | Method of treating or preventing type - 2 diabetes | |
| TR200001040T2 (tr) | Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı | |
| DE69943222D1 (de) | Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b | |
| DE69912743D1 (de) | Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges | |
| ATE402694T1 (de) | Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz | |
| WO2003035048A3 (en) | Methods for the treatment of osteoarthritis and compositions thereof | |
| NO20003813L (no) | FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav | |
| BRPI0408238A (pt) | anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| BRPI0414812A (pt) | método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres |